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Innovations from the Field
Desistance, Self-treatment, or Substitution: Decisions about
Cannabis Use During Pregnancy
Devon Greyson1, PhD, MLIS , Lee Roosevelt2, CNM, PhD, MPH , Carol J. Boyd2,3, MSN, PhD
Cannabis is the most commonly used drug during pregnancy in the United States and Canada, and the American College of Obstetricians and
Gynecologists recommends that all pregnant individuals be screened for cannabis use and counseled regarding potential adverse health impacts
of use. However, those considering or using cannabis during pregnancy report experiencing stigma and lack of information from health care
providers and, thus, frequently rely on friends, family, and the internet for information. This article describes 3 types of decisions individuals
may be making about cannabis use during pregnancy and suggests approaches health care providers may take to minimize judgment and provide
optimal support for informed cannabis use decisions among pregnant individuals. Desistance decisions involve consideration of whether and how
to reduce or stop using during pregnancy. Self-treatment decisions are made by those exploring cannabis to help alleviate troublesome symptoms
such as nausea or anxiety. Substitution decisions entail weighing whether to use cannabis instead of another substance with greater perceived
harms. Health care providers should be able to recognize the various types of cannabis use decisions that are being made in pregnancy and be
ready to have a supportive conversation to provide current and evidence-based information to individuals making desistance, self-treatment, and
substitution decisions. Individuals making desistance decisions may require support with potential adverse consequences such as withdrawal or
return of symptoms for which cannabis was being used, as well as potentially navigating social situations during which cannabis use is expected.
Those making self-treatment decisions should be helped to fully explore treatment options for their symptoms, including evidence on risks and
benefits. Regarding substitution decisions, health care providers should endeavor to help pregnant individuals understand the available evidence
regarding risks and benefits of available options and be open to revisiting the topic over time.
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Cannabis is the most commonly used drug during pregnancy
in the United States and Canada, with prenatal prevalence
rates ranging from 4%1 to 28%2–5 depending on population
and method of measurement. Indications are that although
pregnant individuals overall report less use than nonpregnant
peers,1,6 with growing social and legal acceptance of cannabis,
use during pregnancy is increasing.1,2,7 The American Col-
lege of Obstetricians and Gynecologists recommends that
all pregnant individuals be screened for cannabis use and
counseled regarding potential adverse health consequences
of continued use during pregnancy.8 However, there is little
evidence on whether, or how, counseling for cannabis use is
occurring. When counseling does occur, discussions usually
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focus on legal or child protective implications rather than
potential medical or pregnancy consequences.9 As a result,
pregnant individuals often turn to friends, family, and the
internet for information when they do not receive tailored
information from their care providers.6
Given overall rising rates of cannabis use by reproductive-
aged women as well as by pregnant individuals, it is important
that midwives and other health care providers be equipped
to understand and support pregnant individuals’ cannabis-
related information needs10 and decision-making. This
article draws on the authors’ combined expertise in clinical
midwifery care, substance use research, and health commu-
nication to propose a typology, or classification scheme, for
understanding and supporting decisions about cannabis use
during pregnancy.
WHY A TYPOLOGY OF CANNABIS USE DECISIONS
DURING PREGNANCY IS NEEDED
Use of nonprescription cannabis during pregnancy, similar
to use by nonpregnant populations, may be recreational in
nature, used for therapeutic or medicinal purposes or part
of a substance use disorder, or may fit multiple of these
categories.7,11,12 Cannabis is available in many forms, rang-
ing from smokable dried flower to edible products to topical
creams and oils. Some productsmay contain specific cannabi-
noids such as tetrahydrocannabinol (THC; the primary psy-
choactive compound in cannabis) and/or cannabidiol (CBD;
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✦ Although professional guidance regarding cannabis use during pregnancy may easily tend toward universal recommenda-
tions of abstinence, there are at least 3 unique types of decisions about cannabis use that require different types of support.
✦ Desistance decisions involve consideration of whether and how to reduce or stop using during pregnancy.
✦ Self-treatment decisions are made by those exploring cannabis to help alleviate troublesome symptoms such as nausea or
anxiety.
✦ Substitution decisions entail weighing whether to use cannabis instead of another substance with greater perceived harms.
✦ Providers should be able to recognize the various types of cannabis use decisions that are being made during pregnancy
and be ready to provide relevant, evidence-based information to clients in a nonjudgmental manner.
the federal legality of which is evolving and not always clear
to consumers).
The motivation and decision to use, or to reduce or stop
using, cannabis during pregnancy has clinical import because
it is likely related to health outcomes for both the pregnant
person and the fetus. However, current practice guidelines, as
well as much research to date regarding cannabis use during
pregnancy, do not differentiate between reasons for cannabis
use or for the mode of ingestion. This limits the utility of rec-
ommendations when faced with complex cannabis use deci-
sions, such as substitution of cannabis for another substance
known to cause harms. Understanding the cannabis use de-
cisions faced by pregnant individuals is important for health
care providers to offer the most appropriate information and
support.
Recommendations from governmental bodies13 andmed-
ical associations8 commonly instruct women to abstain from
use during pregnancy and breastfeeding. However, given that
pregnant cannabis users are more likely than nonpregnant
users to meet criteria for cannabis use disorder,14 absolute de-
sistance may not always be simple or practical. People who
experience nausea and vomiting during pregnancy are ap-
proximately twice as likely to use cannabis,15,16 suggesting that
some may be self-medicating for a condition with few ap-
proved and effective therapies. Furthermore, given the known
teratogenic risks of certain medications including antianxiety
drugs, as well as other substances such as alcohol, cannabis
may appear at times to be a reasonable alternative, even
to prior nonusers.17 Typically, informed decision-making in
pregnancy requires health care providers to impart complex
risk information in a way that facilitates understanding and
promotes agency. However, in the case of cannabis use dur-
ing pregnancy there is a risk of information selectivity,18 in
which pregnant individuals receive biased information based
on the perspectives of their health care providers, essentially
undermining the informed decision-making process. There-
fore, many pregnant individuals are making decisions around
cannabis use without support and full information.
In earlier work, Boyd and McCabe proposed an em-
pirically driven typology that categorized the use of con-
trolled medications by motivation to use (self-treatment and
sensation-seeking).19 Their typology has guided numerous re-
search studies20 that advance an understanding of substance
use disorders21 associated with prescribed (legal) and unpre-
scribed (illegal) misuse of therapeutic medications.22–26 The
typology and its use in research has contributed to a bet-
ter understanding of 2 profiles: (1) user subtypes that influ-
ence medical and nonmedical misuse of legal substances, and
(2) misusers of medications for self-treatment.27 However,
Boyd and McCabe’s typology was not developed with self-
treatment decisions during pregnancy in mind, and the ty-
pology did not consider medical cannabis use. The parallels
between cannabis use (both legal and illegal) and controlled
medication use (both legal and illegal) are notable, and for this
reason, we draw on Boyd and McCabe’s typology in develop-




Based on extant research that explored reasons for cannabis
use during pregnancy,5,12 combined with the authors’ clini-
cal practice and research experience on perinatal decision-
making and substance use, we suggest the following typology
for classifying cannabis use decisions during pregnancy: de-
sistance decisions, self-treatment decisions, and substitution
decisions (Table 1).
Type 1: Desistance Decisions
Individuals who are users of cannabis prior to pregnancy fre-
quently face decisions regarding whether and how to reduce
or cease consumption of cannabis or to switch to other forms
of consumption (eg, switch from smoking to edibles or a top-
ical oil) during pregnancy. Desistance decisions may be faced
by those who use cannabis for any reason, including social
and medical reasons. Support required by those considering
desistance during pregnancy may range from clinician affir-
mation to substantial cessation assistance, potentially includ-
ing exploration of alternatives to cannabis. Although for some,
desistance will carry no negative effects, potential health risks
that may be associated with desistance decisions include un-
treated cannabis use disorder, withdrawal, regrettable substi-
tutions, and untreated symptoms that a user may have been
managing with cannabis prior to pregnancy.
Type 2: Self-treatment Decisions
Regardless of past cannabis use history, individuals may con-
sider trying cannabis to treat symptoms that have become
Journal of Midwifery &Women’s Health  www.jmwh.org 97
Table 1. Typology of Cannabis Use Decisions in Pregnancy
Category Definition Example Decisions to Be Discussed
Desistance Used cannabis prior to
becoming pregnant, unsure
of whether to continue
through pregnancy.
Used socially on weekends and for
premenstrual migraines as
needed.
Whether, when, and how to reduce
or stop use during pregnancy.
Self-treatment Regardless of past use, now
considering or using
cannabis for a new issue
during pregnancy.
Considering cannabis to try to
manage nausea and vomiting of
pregnancy.
Whether to use, and if so in what
form and dosage.
How to assess effectiveness.
Substitution Regardless of past use, now
considering or using in place
of another substance
(prescription or otherwise)
perceived to be riskier to
pregnant individual or fetus.
Prescribed paroxetine but
considering switching to a
cannabinoid tincture during
pregnancy because of concerns
over teratogenic effects.
Whether to stop using previous
substance, whether to use
cannabis as a substitute, and, if
so, in what form and dosage.
problematic during pregnancy. Self-treatment may be under-
taken on the recommendation of a friend or family mem-
ber, based on information found online or in print materials,
or, in some cases, there may be no input. Not only are self-
treaters deciding whether to use cannabis, they may face myr-
iad questions regarding form (CBD, THC, or both; tincture,
edibles, smoking, dabbing, etc) and dosing, none of which
have been standardized at this time. Potential negative health
consequences of self-treating include any risks of cannabis use
to fetus and pregnant individual, as well as potential lack of
effective treatment for the underlying condition spurring the
cannabis use.
Type 3: Substitution Decisions
Also affecting individuals across the cannabis use spectrum,
from prior nonusers to habitual users, are decisions regard-
ing whether to use cannabis during pregnancy in place of an-
other substance with greater perceived risks. This may be a
substitution for prescription medication such as psychotropic
or seizure medications, or it could be a harm reduction effort
to reduce use of substances such as alcohol, tobacco, or illicit
opioids. This third category in the typology may involve the
most complex decisions, with the most intense clinical sup-
port needs, as the decision to reduce or stop using the previous
substance is intertwined with the decision to use cannabis. If
the decision ismade to substitute, then these individuals often
face the same decisions as face self-treaters, regarding form
and dosage. Substitution of cannabis for previously-used ef-
fective therapies may also risk untreated symptoms or under-
lying conditions and potential risks to fetus or pregnant indi-
vidual of cannabis use.
It is important to note that these 3 types of decisions
are not mutually exclusive: for example, a regular social user
of cannabis might decide to quit when she discovers she is
pregnant (desistance) but, later during pregnancy, try CBD oil
to alleviate anxiety (self-treatment). Furthermore, the social
context in which a pregnant individual lives may influence
substance use behaviors and complicate the individual’s
ability to seek, access, and use expert advice in cannabis use
decisions.
COUNSELING SUPPORT INCLUSIVE OF THE
COMPLEXITY IN CANNABIS USE DECISIONS
Pregnant individuals considering or using cannabis are moti-
vated by a variety of circumstances and face different types
of decisions. They often have unmet information needs or
experience individual or systemic barriers to obtaining ex-
pert advice to help make and implement their decisions.5,10,28
Accordingly, they require tailored decision-making support,
as some of these decisions are more complex, both socially
and informationally. Finally, those making different types of
cannabis use decisions may experience different health con-
sequences related to their decisions, based on their specific
circumstances.
Cannabis use decisions during pregnancy, whether about
desistance, self-treatment, or substitution, take place in a vari-
ety of contexts, and individuals’ behavior and values vary. Al-
though guidance and discourse regarding cannabis use during
pregnancy may easily tend toward reducing context sensitiv-
ity in favor of blanket recommendations to fully abstain, we
recognize that this may not be a realistic option for all preg-
nant users. Some cannabis use decisions during pregnancy
may be relatively straightforward, such as the choice by an
occasional social user of cannabis to desist for the duration
of pregnancy. However, certain other decisions, such as sub-
stituting cannabis for another substance with greater docu-
mented harms, may be more complex. Furthermore, for in-
dividuals who have experienced stigma and marginalization
by medical or legal services in the past, mere disclosure of
the cannabis decision-making process to a clinician may be
fraught. Thus, substitution decisions would ideally be made
in consultation with an informed and nonjudgmental perina-
tal care provider.
For clinical guidance to be most accurate and effective,
it should reflect the multiplicity of types of cannabis use
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decisions made during pregnancy: those pertaining to de-
sistance, self-treatment, and substitution, to promote effec-
tive counseling during the prenatal period. Information re-
sources and decision-support aids should be tailored to the
real-life cannabis use decisions being made, and counseling
by health care providers should consider the substance use
history and available social support of each decision-maker.
Health care providers should be able to recognize the vari-
ous types of cannabis use decisions that are being made dur-
ing pregnancy and be ready to have a supportive conversa-
tion with current and evidence-based information for indi-
viduals making desistance, self-treatment, and substitution
decisions.
In particular, health care providers should examine their
own biases and assumptions about cannabis use during preg-
nancy, to minimize the risk of appearing judgmental. When
supporting individuals making desistance decisions, atten-
tion should be paid to potential adverse consequences such as
withdrawal or return of symptoms for which cannabis was be-
ing used, and support should be provided for those for whom
cannabis was a part of meaningful social interactions. In cases
of self-treatment decisions, health care providers should help
pregnant individuals explore the full array of treatment op-
tions for their symptoms, and evidence provided on associ-
ated effectiveness and risks. Regarding substitution decisions,
health care providers should endeavor to help pregnant indi-
viduals understand the available evidence regarding risks and
benefits of available options and be open to revisiting the topic
over time.
CONCLUSION
Substantial new investments have been made in recent years
into the science of cannabis, including potential developmen-
tal effects on exposed fetuses or infants, as well as potential
therapeutic uses. Thus, we should soon begin to have more
reliable and empirical evidence regarding risks, and poten-
tial therapeutic benefits, of cannabis during pregnancy.We are
hopeful that with this newmedical and research evidence will
come nuanced and context-sensitive decision-making sup-
ports for anyone considering cannabis use during pregnancy.
Meanwhile, to provide optimal care for pregnant and birthing
individuals, it is important to lay a framework for under-
standing the various desistance, self-treatment, and substi-
tution decisions people make during pregnancy. Health care
providers should be able to acknowledge the various rea-
sons for use and provide the most appropriate information
and support for each individual’s circumstances. Use of this
proposed typology will help health care providers in this
process.
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